Literature DB >> 10604818

The pharmacokinetics of theophylline in premature neonates during the first few days after birth.

M J du Preez1, J H Botha, M L McFadyen, N H Holford.   

Abstract

The aims of the study were to estimate the pharmacokinetic parameters, clearance rate (CL), and volume of distribution (V) of theophylline in premature neonates during the first few days after birth, and to identify factors contributing to interindividual variability. The authors obtained 263 serum concentrations from 105 apneic premature neonates receiving intravenous (IV) theophylline. Mean (SD) birth weight and postnatal ages were 1.3 (0.3) kg and 1.1 (0.3) days, respectively. The data were analyzed using the nonlinear mixed effects model (NONMEM). A one-compartment model with first order elimination was used. The final models were: CL (L/h) = 0.006 * WGT 0.75 * P, V (L) = 0.63 * WGT, WGT = weight (kg) P = 1.47 with oxygen support and 1.0 without oxygen support. The CL in the study population was low, resulting in long half-lives. After inclusion of the above covariates, as well as interoccasion variability, the interindividual variability in CL was 56% and in V was 47%. Interoccasion variability in CL and V was 34% and 35% respectively. Theophylline pharmacokinetics are variable in the premature neonate during the first week of life, and this high variability makes it difficult to predict drug concentrations with the same degree of accuracy as in other populations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604818     DOI: 10.1097/00007691-199912000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Journal:  AAPS PharmSci       Date:  2002

2.  Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 3.  Evaluation of the reproductive and developmental risks of caffeine.

Authors:  Robert L Brent; Mildred S Christian; Robert M Diener
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2011-03-02

Review 4.  Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.

Authors:  Justin D Lutz; Yasushi Fujioka; Nina Isoherranen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-09       Impact factor: 4.481

Review 5.  Treatment of apnea of prematurity.

Authors:  Varsha Bhatt-Mehta; Robert E Schumacher
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation.

Authors:  Hussain Mulla; Fazal Nabi; Sanjiv Nichani; Graham Lawson; R K Firmin; David R Upton
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

Review 7.  Population pharmacokinetic analysis during the first 2 years of life: an overview.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

8.  Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.

Authors:  Adam Frymoyer; Krisa P Van Meurs; David R Drover; Jelena Klawitter; Uwe Christians; Valerie Y Chock
Journal:  Pediatr Res       Date:  2020-09-12       Impact factor: 3.756

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.